Health Professional Radio - Podcast

Dr. Jonathan Cheng, vice president, oncology clinical research, Merck Research Laboratories discusses the recent (June 2019) FDA approval of KEYTRUDA (pembrolizumab) as monotherapy for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other line of therapy.